Company Description
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation.
It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease.
The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome.
In addition, it is developing JNS115, which is in Phase II trial for the treatment of Parkinson’s disease.
The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021.
Jupiter Neurosciences, Inc. was incorporated in 2015 and is headquartered in Jupiter, Florida.
| Country | United States |
| Founded | 2015 |
| IPO Date | Dec 3, 2024 |
| Industry | Pharmaceuticals |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Christer Rosen |
Contact Details
Address: 1001 North US Highway 1, Suite 504 Jupiter, Florida 33477 United States | |
| Phone | 561 406 6154 |
| Website | jupiterneurosciences.com |
Stock Details
| Ticker Symbol | JUNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001679628 |
| Employer ID | 47-4828381 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 424B3 | Prospectus |
| Dec 2, 2024 | 424B4 | Prospectus |
| Dec 2, 2024 | CERT | Certification by an exchange approving securities for listing |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |